Eisai Inc.

WOODCLIFF LAKE, N.J., June 13, 2013 /PRNewswire/ -- Eisai Inc. announced today its platinum level sponsorship of the Citizens United for Research in Epilepsy (CURE) 15(th) Annual Chicago Benefit taking place Thursday, June 13, at Navy Pier, Chicago, IL. (Logo: http://photos.prnewswire.com/prnh/20120413/MM87168LOGO ) CURE is a nonprofit organization ... read more

WOODCLIFF LAKE, N.J., June 7, 2013 /PRNewswire/ -- Eisai Inc. announced today that BELVIQ (pronounced BEL-VEEK) will be available to eligible patients by prescription in the United States beginning June 11. To view the multimedia assets associated with this release, please visit: http://www.multivu.com/mnr/60316-eisai-belviq-civ-chronic-weight-management-tablets-for-overweight-adults (Photo: http://photos.prnewswire.com/prnh/20130607/MM60674 ) BELVIQ was approved by the U.S. Food ... read more

WOODCLIFF LAKE, N.J., May 16, 2013 /PRNewswire/ -- Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announces the appointment of Ricardo Gonzalez Balboa to the position of General Manager, Eisai Laboratorios, S. de R.L. de C.V. (Eisai Mexico), a direct subsidiary of Eisai ... read more

LUGANO, Switzerland and WOODCLIFF LAKE, N.J., May 16, 2013 /PRNewswire/ -- Helsinn Group and Eisai Inc. announced today top-line results from Helsinn's pivotal clinical studies investigating the oral fixed-dose combination of netupitant and palonosetron (NEPA) being evaluated for the proposed indication of prevention of chemotherapy-induced nausea ... read more

WOODCLIFF LAKE, N.J., May 9, 2013 /PRNewswire/ -- Eisai USA Foundation Inc., the charitable arm of Eisai Inc., announces that it has pledged a $1 million donation to the Conquer Cancer Foundation of the American Society of Clinical Oncology (ASCO). The donation, which is being disbursed in ... read more

WOODCLIFF LAKE, N.J., May 7, 2013 /PRNewswire/ -- Eisai Inc. announced today that the U.S. Drug Enforcement Administration (DEA) has placed BELVIQ (pronounced BEL-VEEK) into Schedule IV of the Controlled Substances Act. This information is expected to be published in the Federal Register on May 8, with an effective date ... read more

WOODCLIFF LAKE, N.J., April 18, 2013 /PRNewswire/ -- Eisai Inc. announced today that it is a silver level sponsor of the Epilepsy Foundation's 7(th) Annual National Walk for Epilepsy, a family-oriented, non-competitive event to raise awareness and funds to continue fighting to stop seizures, find a ... read more

WOODCLIFF LAKE, N.J., April 11, 2013 /PRNewswire/ -- Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announces the immediate appointment of Lynn Kramer, MD, to the newly created position of chief clinical officer of Eisai Product Creation Systems. In this role, Dr. Kramer ... read more

WOODCLIFF LAKE, N.J., March 26, 2013 /PRNewswire/ -- Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved ACIPHEX(®) Sprinkle(TM) Delayed-Release Capsules 5mg and 10mg for the treatment of Gastroesophageal Reflux Disease (GERD) in children 1 to 11 years of age for up to 12 weeks. "We ... read more

WOODCLIFF LAKE, N.J., Feb. 14, 2013 /PRNewswire/ -- Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to its investigational drug lenvatinib (E7080) for follicular, medullary, anaplastic and metastatic or locally advanced papillary thyroid cancer. (Logo: http://photos.prnewswire.com/prnh/20120413/MM87168LOGO ) The Orphan Drug ... read more

WOODCLIFF LAKE, NJ -- (Marketwire) -- 11/10/09 -- Eisai Inc. introduced a new educational program today to help parents and caregivers of patients with Lennox-Gastaut syndrome (LGS), a rare form of epilepsy in which patients have frequent seizures of multiple types. The program is centered on the new Web resource, www.LivingWithLGS.com, offering updated ... read more